Ignite Creation Date:
2024-05-05 @ 11:48 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00133328
Status:
UNKNOWN
Last Update Posted:
2005-10-28
First Post:
2005-08-22
Brief Title:
A Morbidity-Mortality and Remodeling Study With Valsartan
Sponsor:
Jikei University School of Medicine
Organization:
Jikei University School of Medicine
Study Overview
Official Title:
A Morbi-Mortality and Remodeling Study With Valsartan in Patients With Hypertension and Cardiovascular Disease
Status:
UNKNOWN
Status Verified Date:
2002-01
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The JIKEI HEART Study has been designed to investigate whether concomitant treatment with valsartan an angiotensin II receptor blocker ARB in addition to conventional treatment will improve the prognosis of 3000 Japanese patients with cardiovascular diseases
Detailed Description:
Several recent clinical trials have demonstrated that angiotensin II receptor blockers ARBs have cardiovascular as well as renal protective effects However it is a problem that the number of Asian patients is very little in these trials The researchers examine the treatment meaning by ARB about the prognosis of the patient who amalgamates either among high blood pressure the ischemic heart disease and congestive heart failures
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None